Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.61 USD
Change Today -0.17 / -1.94%
Volume 1.0M
AGEN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

agenus inc (AGEN) Key Developments

Agenus Inc. Presents at JMP Securities Life Sciences Conference, Jun-23-2015 12:00 PM

Agenus Inc. Presents at JMP Securities Life Sciences Conference, Jun-23-2015 12:00 PM. Venue: The St. Regis New York, 2 East 55th Street, New York, NY 10022, United States.

Agenus Inc. Appoints C. Evan Ballantyne as Chief Financial Officer

Agenus Inc. announced the appointment of C. Evan Ballantyne as the company’s Chief Financial Officer, effective immediately. Mr. Ballantyne will be responsible for all aspects of the company’s financial, accounting, investor relations and corporate communication functions. Mr. Ballantyne brings more than 30 years of financial and operations experience to Agenus. Most recently, Mr. Ballantyne served as the Chief Financial Officer at Synthetic Biologics Inc. from February 2012 to May 2015.

Merck Extends Immuno-Oncology Collaboration with Agenus Inc

Agenus Inc. announced that Merck, through a subsidiary, has extended its collaborative research term under its existing collaboration and license agreement with Agenus, for the discovery and development of therapeutic antibodies to Merck proprietary immune checkpoints for the treatment of cancer. Under the terms of the original agreement, Agenus will discover and optimize fully human antibodies against two undisclosed Merck checkpoint targets using the Retrocyte Display platform. Merck will be responsible for the further development and commercialization of candidates generated under the collaboration. The discovery phase has been extended to April 2016. As previously disclosed, under the terms of the agreement, Agenus is eligible to receive approximately $100 million in milestone payments as well as royalties on worldwide product sales.

Agenus, Merck Extend Immuno-Oncology Collaboration

Agenus (AGEN) and Merck (MRK) have extended the research term under their existing collaboration and license agreement for the discovery and development of therapeutic antibodies. Under the amended agreement, Agenus is now given until April 2016 to discover and optimize fully human antibodies against two undisclosed Merck checkpoint targets using the Retrocyte Display platform. Merck will still be responsible for the further development and commercialization of candidates generated under the collaboration. Furthermore, Agenus is eligible to receive approximately $100 million in milestone payments as well as royalties on worldwide product sales.

Agenus Inc. Provides Update on Phase 2 Data of Prophage in Newly Diagnosed GBM

Agenus Inc. announced that patients with newly diagnosed Glioblastoma Multiforme (GBM) treated with Prophage (AGEN’s individualized heat shock protein (HSP)-based cancer vaccine) plus Standard of Care (SOC) show substantially longer Progression Free Survival (PFS) and median Overall Survival (mOS) compared to historical SOC data. GBM patients show evidence of tumor-mediated immunosuppression prior to treatment, measurable in part by greater expression of PD-L1 (Programmed Death Receptor – Ligand - on monocytic white cells in their peripheral blood. These elevations of peripheral blood monocyte PD-L1 correlate with elevation of PD-L1 expressing macrophages in their brain tumors, potentially working against effective immuno-therapy. When outcomes in this study were analyzed based on the extent of monocyte PD-L1 expression, the 50% of patients with less elevated PD-L1 showed markedly better PFS and mOS than historical SOC: PFS of 27 months versus 5-9 months and mOS of 45 months versus 15-19 months. Further, more than a third of these patients remain alive for more than three years from initial treatment, and more than 80% of these have not progressed. Prophage plus SOC also gave longer PFS and mOS than historical SOC data in the 50% of patients with greater monocyte PD-L1 elevation, although the differences were less pronounced. This raises the possibility of an improved Prophage benefit by combination with Checkpoint Modulating Antibodies (CPMs) that block PD-1 or PD-L1. Additionally, the reported data suggest that Prophage added to SOC leads to longer mPFS and mOS regardless of MGMT methylation status, a known predictor of response to SOC. When Prophage is added to SOC in MGMT methylated patients in this study, the mOS was 44.7 months, compared to 23 months reported for comparable MGMT methylated GBM patients on SOC alone in recent controlled trials (RTOG 0825). MGMT methylation and PD-L1 expression on monocytes appear to be independent predictive markers in these patients. Although the apparent benefit of adding Prophage to SOC was observable in all subgroups of patients compared to historical SOC outcomes, the prolongations of mPFS and mOS are especially striking in patients with high MGMT and less elevated circulating monocyte expression of PD-L1: in this sub-group more than half the patients live for 4 years from initial treatment Study details: The Phase 2 single-arm trial enrolled forty-six adult patients with newly diagnosed GBM from eight centers in the U.S. Each patient received SOC (surgical resection followed by chemoradiation). Within five weeks of completing radiotherapy, patients received continuing adjuvant temozolomide as well as weekly Prophage injections for four weeks followed by monthly Prophage injections until the depletion of vaccine or tumor progression. The primary endpoints of the trial were PFS and mOS.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGEN:US $8.61 USD -0.17

AGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGEN.
View Industry Companies
 

Industry Analysis

AGEN

Industry Average

Valuation AGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 56.2x
Price/Book 13.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 60.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGENUS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.